Patent ID: 8703180

Claim:
A method of treating compromised cardiac tissue within a mammal, comprising: advancing a delivery device through a lumen of a blood vessel to a treatment region wherein the treatment region is compromised cardiac tissue; and introducing through the delivery device: a first bioerodable carrier platform capable of sustained release of a first growth factor; at least one second different bioerodable carrier platform capable of sustained release of a second growth factor, wherein the second different bioerodable carrier platform is a two-component hydrogel selected from the group consisting of hyaluronic acid, fibrin glue, alginate and silk-elastin copolymers and wherein the second bioerodable carrier platform is formed upon separately delivering two precursors of the two-component hydrogel to the compromised cardiac tissue, wherein the two precursors are in a liquid state prior to delivering and mix to form the two-component gel after delivering; and at least one cell type, wherein a rate of release of the first growth factor from the first bioerodable carrier platform is faster than a rate of release of the second growth factor from the second bioerodable carrier platform, and wherein the first growth factor and the second growth factor are different and each of the first growth factor and the second growth factor have a different function when delivered to the compromised cardiac tissue such that cell survival followed by cell homing is enhanced.